FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034664140> ?p ?o ?g. }

• W2034664140 endingPage "388" @default.
• W2034664140 startingPage "381" @default.
• W2034664140 abstract "BackgroundPostexposure prophylaxis (PEP) with oseltamivir (Tamiflu) has been shown to be effective and is approved in children exposed to a case of influenza in a household setting. Given limited healthcare budgets, it is important to understand the costs and cost effectiveness of PEP in children.PurposeThis study aims to estimate the cost effectiveness of oseltamivir PEP for children aged 1–12 years in the U.S.MethodsA decision-tree model with a 1-year time horizon was used to assess the cost effectiveness of oseltamivir PEP for 10 days at approved doses compared with no prophylaxis for children aged 1–12 years who were exposed to a household index case of influenza from the U.S. societal and payer perspectives. Model inputs included U.S. influenza epidemiology data, efficacy data from oseltamivir PEP clinical trials, direct medical resource use and costs for PEP and influenza treatment derived from large U.S. databases, and indirect costs based on caregiver lost productivity. Base-case estimates were tested in extensive sensitivity analyses.ResultsFor the societal perspective, the model estimated 12,184 fewer cases of influenza per 100,000 children exposed and an incremental cost-effectiveness ratio of $41,452 per quality-adjusted life-year (QALY) gained. Results were most sensitive to the influenza attack rate, PEP protective efficacy, and prescribing patterns for initiating PEP. Probabilistic sensitivity analyses showed that oseltamivir PEP was likely to be cost effective for all willingness-to-pay threshold values above $34,300 per QALY gained. Results were similar for the payer perspective.ConclusionsAlthough there is no official cost-effectiveness threshold in the U.S., results from the current study show that when compared with no prophylaxis, oseltamivir PEP for children has cost-effectiveness ratios similar to those of vaccines for preventing influenza. Postexposure prophylaxis (PEP) with oseltamivir (Tamiflu) has been shown to be effective and is approved in children exposed to a case of influenza in a household setting. Given limited healthcare budgets, it is important to understand the costs and cost effectiveness of PEP in children. This study aims to estimate the cost effectiveness of oseltamivir PEP for children aged 1–12 years in the U.S. A decision-tree model with a 1-year time horizon was used to assess the cost effectiveness of oseltamivir PEP for 10 days at approved doses compared with no prophylaxis for children aged 1–12 years who were exposed to a household index case of influenza from the U.S. societal and payer perspectives. Model inputs included U.S. influenza epidemiology data, efficacy data from oseltamivir PEP clinical trials, direct medical resource use and costs for PEP and influenza treatment derived from large U.S. databases, and indirect costs based on caregiver lost productivity. Base-case estimates were tested in extensive sensitivity analyses. For the societal perspective, the model estimated 12,184 fewer cases of influenza per 100,000 children exposed and an incremental cost-effectiveness ratio of $41,452 per quality-adjusted life-year (QALY) gained. Results were most sensitive to the influenza attack rate, PEP protective efficacy, and prescribing patterns for initiating PEP. Probabilistic sensitivity analyses showed that oseltamivir PEP was likely to be cost effective for all willingness-to-pay threshold values above $34,300 per QALY gained. Results were similar for the payer perspective. Although there is no official cost-effectiveness threshold in the U.S., results from the current study show that when compared with no prophylaxis, oseltamivir PEP for children has cost-effectiveness ratios similar to those of vaccines for preventing influenza." @default.
• W2034664140 created "2016-06-24" @default.
• W2034664140 creator A5014156717 @default.
• W2034664140 creator A5028393470 @default.
• W2034664140 creator A5085964220 @default.
• W2034664140 date "2009-11-01" @default.
• W2034664140 modified "2023-09-27" @default.
• W2034664140 title "Oseltamivir for Influenza Postexposure Prophylaxis" @default.
• W2034664140 cites W1928788567 @default.
• W2034664140 cites W1933516644 @default.
• W2034664140 cites W1960753282 @default.
• W2034664140 cites W1965955024 @default.
• W2034664140 cites W1977775160 @default.
• W2034664140 cites W1985440659 @default.
• W2034664140 cites W1988374492 @default.
• W2034664140 cites W1990817586 @default.
• W2034664140 cites W1994119684 @default.
• W2034664140 cites W2001187841 @default.
• W2034664140 cites W2005349838 @default.
• W2034664140 cites W2008651219 @default.
• W2034664140 cites W2009043457 @default.
• W2034664140 cites W2016525580 @default.
• W2034664140 cites W2024882643 @default.
• W2034664140 cites W2026309239 @default.
• W2034664140 cites W2026979950 @default.
• W2034664140 cites W2029414780 @default.
• W2034664140 cites W2035431567 @default.
• W2034664140 cites W2039737448 @default.
• W2034664140 cites W2046335330 @default.
• W2034664140 cites W2047562582 @default.
• W2034664140 cites W2054640272 @default.
• W2034664140 cites W2058144955 @default.
• W2034664140 cites W2059316621 @default.
• W2034664140 cites W2078178793 @default.
• W2034664140 cites W2082937130 @default.
• W2034664140 cites W2091908067 @default.
• W2034664140 cites W2095981561 @default.
• W2034664140 cites W2105915614 @default.
• W2034664140 cites W2111155300 @default.
• W2034664140 cites W2117512155 @default.
• W2034664140 cites W2130060383 @default.
• W2034664140 cites W2130441728 @default.
• W2034664140 cites W2135476128 @default.
• W2034664140 cites W2136956292 @default.
• W2034664140 cites W2138915100 @default.
• W2034664140 cites W2139841187 @default.
• W2034664140 cites W2145230724 @default.
• W2034664140 cites W2151805197 @default.
• W2034664140 cites W2162461975 @default.
• W2034664140 cites W2312219549 @default.
• W2034664140 cites W2315519241 @default.
• W2034664140 cites W2317474745 @default.
• W2034664140 cites W2607451627 @default.
• W2034664140 cites W4256215782 @default.
• W2034664140 doi "https://doi.org/10.1016/j.amepre.2009.08.012" @default.
• W2034664140 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19840692" @default.
• W2034664140 hasPublicationYear "2009" @default.
• W2034664140 type Work @default.
• W2034664140 sameAs 2034664140 @default.
• W2034664140 citedByCount "6" @default.
• W2034664140 countsByYear W20346641402012 @default.
• W2034664140 countsByYear W20346641402013 @default.
• W2034664140 countsByYear W20346641402016 @default.
• W2034664140 countsByYear W20346641402018 @default.
• W2034664140 countsByYear W20346641402019 @default.
• W2034664140 crossrefType "journal-article" @default.
• W2034664140 hasAuthorship W2034664140A5014156717 @default.
• W2034664140 hasAuthorship W2034664140A5028393470 @default.
• W2034664140 hasAuthorship W2034664140A5085964220 @default.
• W2034664140 hasConcept C112930515 @default.
• W2034664140 hasConcept C121955636 @default.
• W2034664140 hasConcept C126322002 @default.
• W2034664140 hasConcept C144133560 @default.
• W2034664140 hasConcept C187212893 @default.
• W2034664140 hasConcept C194828623 @default.
• W2034664140 hasConcept C2778283251 @default.
• W2034664140 hasConcept C2779134260 @default.
• W2034664140 hasConcept C2780374985 @default.
• W2034664140 hasConcept C3008058167 @default.
• W2034664140 hasConcept C3013748606 @default.
• W2034664140 hasConcept C3019080777 @default.
• W2034664140 hasConcept C512399662 @default.
• W2034664140 hasConcept C524204448 @default.
• W2034664140 hasConcept C6964187 @default.
• W2034664140 hasConcept C71924100 @default.
• W2034664140 hasConcept C99454951 @default.
• W2034664140 hasConceptScore W2034664140C112930515 @default.
• W2034664140 hasConceptScore W2034664140C121955636 @default.
• W2034664140 hasConceptScore W2034664140C126322002 @default.
• W2034664140 hasConceptScore W2034664140C144133560 @default.
• W2034664140 hasConceptScore W2034664140C187212893 @default.
• W2034664140 hasConceptScore W2034664140C194828623 @default.
• W2034664140 hasConceptScore W2034664140C2778283251 @default.
• W2034664140 hasConceptScore W2034664140C2779134260 @default.
• W2034664140 hasConceptScore W2034664140C2780374985 @default.
• W2034664140 hasConceptScore W2034664140C3008058167 @default.
• W2034664140 hasConceptScore W2034664140C3013748606 @default.
• W2034664140 hasConceptScore W2034664140C3019080777 @default.

• next